Source: Annual Congress 2004 - Chemotherapy, targeted therapies costs and outcomes
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
G. Buccheri, D. Ferrigno, M. C. Giordano (Cuneo, Italy). Cisplatin/vinorelbine remains a valid option for the front-line chemotherapy of NSCLC. Eur Respir J 2004; 24: Suppl. 48, 1939

Member's Comments

No comment yet.

Related content which might interest you: Neoadjuvant chemotherapy for NSCLC, lung function and surgical therapy – which is their connection? Source: International Congress 2019 – Lung function testing: from experimental investigations to clinical applications Year: 2019 What outcome after the prescription of neoadjuvant chemotherapy in lung cancer? Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Adjuvant and neoadjuvant therapy in nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2006 - Clinical year in review Year: 2006 Definitive radiation therapy for elderly patients with stage III NSCLC not candidates for combined chemoradiation Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Impact of neoadjuvant therapies on surgical indications and early postoperative outcome Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Adjuvant therapy in NSCLC Source: Annual Congress 2007 - Clinical year in review Year: 2007 Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Palliative chemotherapy in non-small cell lung cancer (NSCLC): first-line therapy data from the ACTION observational study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting Source: Eur Respir J 2003; 22: Suppl. 45, 163s Year: 2003 Early stage nonsmall-cell lung cancer: therapeutic options (surgery, adjuvant and neoadjuvant therapy) Source: Annual Congress 2011 - PG10 Management of thoracic tumours in practice: a HERMES basic course Year: 2011 Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Combined modality treatment for NSCLC Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer Year: 2007 Use of 2nd-line polychemotherapy in advanced nonsmall cell lung cancer – a reasonable approach Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003 Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Symptomatic benefit of short regimen of palliative radiotherapy for elderly patients with locally advanced non small cell lung cancer Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010